Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2020-11-09 5:26 pm Purchase | 2020-10-28 | 13G | MIRAGEN THERAPEUTICS INC MGEN | BIOTECHNOLOGY VALUE FUND L P | 7,584,219 9.990% | 7,584,219![]() (New Position) | Filing History |
2020-11-03 4:39 pm Sale | 2020-10-30 | 13G | BioLineRx Ltd. BLRX | BIOTECHNOLOGY VALUE FUND L P | 148,671 1.900% | -632,391![]() (-80.97%) | Filing History |
2020-10-20 08:59 am Purchase | 2020-05-22 | 13G | ContraFect Corporation CFRX | BIOTECHNOLOGY VALUE FUND L P | 36,361 9.990% | 36,361![]() (New Position) | Filing History |
2020-10-13 5:18 pm Sale | 2020-10-09 | 13D | PHAXIAM Therapeutics S.A. PHXM | BIOTECHNOLOGY VALUE FUND L P | 44,619 23.500% | -857![]() (-1.88%) | Filing History |
2020-10-09 5:20 pm Unchanged | 2020-10-07 | 13D | XOMA Corporation XOMA | BIOTECHNOLOGY VALUE FUND L P | 4,182,243 38.000% | 0 (Unchanged) | Filing History |
2020-10-08 5:26 pm Purchase | 2020-10-06 | 13D | FIVE PRIME THERAPEUTICS INC FPRX | BIOTECHNOLOGY VALUE FUND L P | 8,364,353 22.800% | 581,352![]() (+7.47%) | Filing History |
2020-10-05 5:26 pm Purchase | 2020-10-01 | 13G | NOVUS THERAPEUTICS INC NVUS | BIOTECHNOLOGY VALUE FUND L P | 195,326 15.600% | 195,326![]() (New Position) | Filing History |
2020-09-23 5:28 pm Purchase | 2020-09-21 | 13D | XOMA Corporation XOMA | BIOTECHNOLOGY VALUE FUND L P | 4,182,243 38.000% | 156,086![]() (+3.88%) | Filing History |
2020-08-25 5:27 pm Purchase | 2020-08-21 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 2,630,662 5.900% | 2,630,662![]() (New Position) | Filing History |
2020-08-25 12:32 pm Unchanged | 2020-08-25 | 13D | PRINCIPIA BIOPHARMA INC PRNB | BIOTECHNOLOGY VALUE FUND L P | 5,231,900 15.700% | 0 (Unchanged) | Filing History |
2020-08-19 1:49 pm Purchase | 2020-08-17 | 13G | PRINCIPIA BIOPHARMA INC PRNB | BIOTECHNOLOGY VALUE FUND L P | 5,231,900 15.700% | 3,515,166![]() (+204.76%) | Filing History |
2020-07-20 4:35 pm Purchase | 2020-07-08 | 13G | Therapeutics Acquisition Corp. RACA | BIOTECHNOLOGY VALUE FUND L P | 1,000,000 5.900% | 1,000,000![]() (New Position) | Filing History |
2020-07-20 4:22 pm Purchase | 2020-07-10 | 13D | Inventiva S.A. IVA | BIOTECHNOLOGY VALUE FUND L P | 7,958,138 20.700% | 7,958,138![]() (New Position) | Filing History |
2020-07-16 5:11 pm Purchase | 2020-07-06 | 13G | UNUM THERAPEUTICS INC UMRX | BIOTECHNOLOGY VALUE FUND L P | 4,154,000 9.990% | 4,154,000![]() (New Position) | Filing History |